U.S. flag An official website of the United States government
  1. Home
  2. Drugs
  3. Guidance, Compliance, & Regulatory Information
  4. Enforcement Activities by FDA
  5. Regulatory Action Against Ranbaxy
  1. Guidance, Compliance, & Regulatory Information

Regulatory Action Against Ranbaxy

Regulatory Action Against Ranbaxy

These facilities are now owned by Sun Pharmaceutical.

Consent Decree for Toansa, India, Facility
Import Alert and Consent Decree for Mohali, India, Facility
  • FDA Press Release: FDA prohibits manufacture of FDA-regulated drugs from Ranbaxy’s Mohali, India, plant and issues import alert (9/16/2013)
Department of Justice Action Against Ranbaxy
  • DOJ News Release: Generic Drug Manufacturer Ranbaxy Pleads Guilty and Agrees to Pay $500 Million to Resolve False Claims Allegations, CGMP Violations and False Statements to the FDA (5/13/2013)
Consent Decree for Paonta Sahib, Batamandi, and Dewas, India, Facilities and Ohm Laboratories in Gloversville, N.Y.
  • FDA News Release: Department of Justice files consent decree of permanent injunction against Ranbaxy (1/25/2012)
Application Integrity Policy Action for Paonta Sahib, India, Facility
Import Alert for Dewas and Paonta Sahib, India, Facilities

Additional Warning Letters

Back to Top